Direct-to-consumer digital care firm Hims & Hers is the newest digital well being firm to announce it would add GLP-1 drugs to its choices to help customers with weight-loss administration.
The San Francisco-based firm, which launched its weight-loss program in December, stated customers will now have entry to generic and 503B compounded injectable drugs and oral remedy kits for weight administration that begin at $199 a month.
In a press release, the corporate stated its drugs will probably be extra available than model names like Ozempic or Wegovy because of a partnership with a U.S. producer of generic variations of GLP-1s.
“We’ve leveraged our dimension and scale to safe entry to one of many highest-quality provides of compounded GLP-1 injections obtainable right now. We’re passing that entry and worth alongside to our prospects, who deserve the very best normal of scientific security and efficacy to fulfill their objectives, and we’re doing it in a secure, inexpensive method that others can’t ship,” Andrew Dudum, CEO and cofounder of Hims & Hers, stated in a press release.
THE LARGER TREND
Researchers proceed to judge the protection of GLP-1 drugs for long-term use.
One research revealed within the International Journal of Clinical Pharmacy revealed there may be growing knowledge on the potential of pancreatic carcinoma related to GLP-1 receptor agonists.
Nonetheless, one other research revealed in JAMA Network Open confirmed that researchers discovered no help for elevated pancreatic most cancers incidence after seven years following the beginning of GLP-1 therapy.
Different corporations which have added GLP-1-focused choices to their platform embody digital chronic-condition-management firm Lark Health.
Digital weight-loss firm Noom introduced its business enterprise, Noom for Work, and nationwide pharmacy profit supervisor Liviniti have been partnering to offer plan sponsors and their workers a digital GLP-1 Companion for power weight circumstances.
